Table 3 Adverse events (AEs) occurring in more than 10% of either treatment group
Gefitinib (N = 22) | All Grades | CTC Grade 3 or 4 |
|---|---|---|
Skin-related AEs | 14 (63.6%) | 1 (4.5%) |
ALT | 14 (63.6%) | 5 (22.7%) |
AST | 12 (54.5%) | 3 (13.6%) |
Anemia | 11 (50.0%) | 0 |
Hypoalbminemia | 9 (40.9%) | 0 |
Anorexia | 6 (27.3%) | 0 |
Fatigue | 6 (27.3%) | 0 |
Diarrhea | 6 (27.3%) | 0 |
ALP | 6 (27.3%) | 0 |
VNR or GEM (N = 32) | All Grades | CTC Grade 3 or 4 |
Anemia | 23 (71.9%) | 4 (12.5%) |
Leukocytopenia | 21 (65.6%) | 15 (46.9%) |
Neutropenia | 20 (62.5%) | 15 (46.9%) |
Fatigue | 18 (56.3%) | 2 (6.3%) |
Anorexia | 12 (37.5%) | 3 (9.4%) |
Thrombocytopenia | 12 (37.5%) | 1 (3.1%) |
ALT | 12 (37.5%) | 0 |
Nausea | 11 (34.4%) | 2 (6.3%) |
Constipation | 9 (28.1%) | 1 (3.1%) |
AST | 9 (28.1%) | 0 |
Hyponatremia | 5 (15.6%) | 2 (6.3%) |
Hyperkalemia | 5 (15.6%) | 0 |
Hypocalcemia | 5 (15.6%) | 0 |
Febrile neutropenia | 4 (12.5%) | 4 (12.5%) |